)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Apogee Therapeutics
Apogee Therapeutics (APGE) investor relations material
Apogee Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Key clinical data and development progress
Phase II data in atopic dermatitis showed rapid itch relief and significant lesional benefit, with a focus on extending dosing intervals to every 3–6 months without sacrificing efficacy.
Phase 1b asthma study demonstrated up to 60% FeNO reduction and durable effect out to 8 months, supporting potential for quarterly dosing and label expansion.
Maintenance data will benchmark against Dupixent and Ebglyss, focusing on responder rates at week 52 and safety, particularly conjunctivitis rates.
Conjunctivitis events were mostly mild, short-lived, and not a significant concern for patients or physicians.
No injection site reactions observed in Part A; low ADA rates with no impact on efficacy, supporting a favorable safety profile.
Commercial and strategic outlook
Asthma indication unlocks additional market potential, leveraging overlap with atopic dermatitis and expanding reach to allergists and pulmonologists.
Launch planned for 2029, with over $900 million in cash runway through Phase III top-line data and preparations for a 150-rep sales force.
Optimized manufacturing and formulation processes aim for low cost of goods and efficient scale-up.
Product profile designed to meet needs of patients, physicians, payers, and regulatory authorities.
Positioned as the next first-line agent, aiming to challenge current market leaders in atopic dermatitis.
Pipeline and future plans
Combination therapies, including a fixed-dose IL-13/OX40 ligand, are in development as potential second-line options, with head-to-head studies against Dupixent ongoing.
Safety concerns with competitor molecules reinforce the focus on efficacy and safety in combination approaches.
Broader portfolio strategy includes potential expansion into respiratory and other inflammatory conditions.
Future work may explore additional indications such as eosinophilic esophagitis, where less frequent dosing could offer significant patient benefit.
Ongoing engagement with stakeholders to ensure product differentiation and address evolving market needs.
How will maintenance data validate dosing thesis?
How does asthma data impact payer negotiations?
How does APG279 strategy differ from competitors?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Apogee Therapeutics earnings date
Q4 20254 Mar, 2026
Apogee Therapeutics
Next Apogee Therapeutics earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apogee Therapeutics Inc. (APGE) is a biotechnology company engaged in the development of differentiated biologics for the treatment of various inflammatory and immunology (I&I) diseases, including atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and other conditions with high unmet medical needs. The company's approach is focused on creating best-in-class therapies that aim to improve upon the current standard of care for these conditions. The company is headquartered in San Francisco, California, and Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage